FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115202206> ?p ?o ?g. }

• W3115202206 endingPage "271" @default.
• W3115202206 startingPage "271" @default.
• W3115202206 abstract "In the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, agents targeting genetic tumor abnormalities are administered to patients. In the NCI-MATCH subprotocol EAY131-Y trial, patients with an AKT1 E17K-mutated metastatic tumor received the pan-AKT inhibitor capivasertib.To assess the objective response rate (ORR) of capivasertib in patients with an AKT1 E17K-mutated tumor.Between July 13, 2016, and August 10, 2017, patients in the NCI-MATCH trial were enrolled and assigned to the subprotocol EAY131-Y nonrandomized trial. Patients included adults with an AKT1 E17K-mutated metastatic tumor that had progressed with standard treatment, and these patients were assigned to receive capivasertib. Tumor assessments were repeated every 2 cycles. Data analysis of this evaluable population was performed from November 8, 2019, to March 12, 2020.The study treatment was capivasertib, 480 mg, orally twice daily for 4 days on and 3 days off weekly in 28-day cycles until disease progression or unacceptable toxic effect. If patients continued hormone therapy for metastatic breast cancer, the capivasertib dose was 400 mg.The primary end point was the ORR (ie, complete response [CR] and partial response) according to the Response Evaluation Criteria in Solid Tumors criteria, version 1.1. Secondary end points included progression-free survival (PFS), 6-month PFS, overall survival, and safety.In total, 35 evaluable and analyzable patients were included, of whom 30 were women (86%), and the median (range) age was 61 (32-73) years. The most prevalent cancers were breast (18 [51%]), including 15 patients with hormone receptor (HR)-positive/ERBB2-negative and 3 with triple-negative disease, and gynecologic (11 [31%]) cancers. The ORR rate was 28.6% (95% CI, 15%-46%). One patient with endometrioid endometrial adenocarcinoma achieved a CR and remained on therapy at 35.6 months. Patients with confirmed partial response had the following tumor types: 7 had HR-positive/ERBB2-negative breast cancer, 1 had uterine leiomyosarcoma, and 1 had oncocytic parotid gland carcinoma and continued receiving treatment at 28.8 months. Sixteen patients (46%) had stable disease as the best response, 2 (6%) had progressive disease, and 7 (20%) were not evaluable. With a median follow-up of 28.4 months, the overall 6-month PFS rate was 50% (95% CI, 35%-71%). Capivasertib was discontinued because of adverse events in 11 of 35 patients (31%). Grade 3 treatment-related adverse events included hyperglycemia (8 [23%]) and rash (4 [11%]). One grade 4 hyperglycemic adverse event was reported.This nonrandomized trial found that, in patients with an AKT1 E17K-mutated tumor treated with capivasertib, a clinically significant ORR was achieved, including 1 CR. Clinically meaningful activity with single-agent capivasertib was demonstrated in refractory malignant neoplasms, including rare cancers.ClinicalTrials.gov Identifier: NCT00700882." @default.
• W3115202206 created "2021-01-05" @default.
• W3115202206 creator A5018045003 @default.
• W3115202206 creator A5021514634 @default.
• W3115202206 creator A5023174631 @default.
• W3115202206 creator A5028533192 @default.
• W3115202206 creator A5033174879 @default.
• W3115202206 creator A5035449610 @default.
• W3115202206 creator A5040238984 @default.
• W3115202206 creator A5040419960 @default.
• W3115202206 creator A5043946489 @default.
• W3115202206 creator A5045409088 @default.
• W3115202206 creator A5045588395 @default.
• W3115202206 creator A5050844235 @default.
• W3115202206 creator A5055462512 @default.
• W3115202206 creator A5055769016 @default.
• W3115202206 creator A5068335479 @default.
• W3115202206 creator A5075568815 @default.
• W3115202206 creator A5078129443 @default.
• W3115202206 creator A5078636533 @default.
• W3115202206 creator A5083795244 @default.
• W3115202206 creator A5091723132 @default.
• W3115202206 date "2021-02-01" @default.
• W3115202206 modified "2023-09-30" @default.
• W3115202206 title "Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor" @default.
• W3115202206 cites W1782443628 @default.
• W3115202206 cites W1913159188 @default.
• W3115202206 cites W1966133006 @default.
• W3115202206 cites W2018023891 @default.
• W3115202206 cites W2019607817 @default.
• W3115202206 cites W2042302972 @default.
• W3115202206 cites W2057312164 @default.
• W3115202206 cites W2082887122 @default.
• W3115202206 cites W2084875329 @default.
• W3115202206 cites W2106036365 @default.
• W3115202206 cites W2117497402 @default.
• W3115202206 cites W2144957807 @default.
• W3115202206 cites W2221429738 @default.
• W3115202206 cites W2388163742 @default.
• W3115202206 cites W2397963384 @default.
• W3115202206 cites W2586898085 @default.
• W3115202206 cites W2613226689 @default.
• W3115202206 cites W2745616170 @default.
• W3115202206 cites W2891700678 @default.
• W3115202206 cites W2921352499 @default.
• W3115202206 cites W2947033139 @default.
• W3115202206 cites W3000323522 @default.
• W3115202206 doi "https://doi.org/10.1001/jamaoncol.2020.6741" @default.
• W3115202206 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7774047" @default.
• W3115202206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33377972" @default.
• W3115202206 hasPublicationYear "2021" @default.
• W3115202206 type Work @default.
• W3115202206 sameAs 3115202206 @default.
• W3115202206 citedByCount "40" @default.
• W3115202206 countsByYear W31152022062021 @default.
• W3115202206 countsByYear W31152022062022 @default.
• W3115202206 countsByYear W31152022062023 @default.
• W3115202206 crossrefType "journal-article" @default.
• W3115202206 hasAuthorship W3115202206A5018045003 @default.
• W3115202206 hasAuthorship W3115202206A5021514634 @default.
• W3115202206 hasAuthorship W3115202206A5023174631 @default.
• W3115202206 hasAuthorship W3115202206A5028533192 @default.
• W3115202206 hasAuthorship W3115202206A5033174879 @default.
• W3115202206 hasAuthorship W3115202206A5035449610 @default.
• W3115202206 hasAuthorship W3115202206A5040238984 @default.
• W3115202206 hasAuthorship W3115202206A5040419960 @default.
• W3115202206 hasAuthorship W3115202206A5043946489 @default.
• W3115202206 hasAuthorship W3115202206A5045409088 @default.
• W3115202206 hasAuthorship W3115202206A5045588395 @default.
• W3115202206 hasAuthorship W3115202206A5050844235 @default.
• W3115202206 hasAuthorship W3115202206A5055462512 @default.
• W3115202206 hasAuthorship W3115202206A5055769016 @default.
• W3115202206 hasAuthorship W3115202206A5068335479 @default.
• W3115202206 hasAuthorship W3115202206A5075568815 @default.
• W3115202206 hasAuthorship W3115202206A5078129443 @default.
• W3115202206 hasAuthorship W3115202206A5078636533 @default.
• W3115202206 hasAuthorship W3115202206A5083795244 @default.
• W3115202206 hasAuthorship W3115202206A5091723132 @default.
• W3115202206 hasConcept C121608353 @default.
• W3115202206 hasConcept C126322002 @default.
• W3115202206 hasConcept C141071460 @default.
• W3115202206 hasConcept C143998085 @default.
• W3115202206 hasConcept C154137905 @default.
• W3115202206 hasConcept C185592680 @default.
• W3115202206 hasConcept C190283241 @default.
• W3115202206 hasConcept C203092338 @default.
• W3115202206 hasConcept C2775930923 @default.
• W3115202206 hasConcept C2776694085 @default.
• W3115202206 hasConcept C2780739268 @default.
• W3115202206 hasConcept C2908647359 @default.
• W3115202206 hasConcept C530470458 @default.
• W3115202206 hasConcept C535046627 @default.
• W3115202206 hasConcept C55493867 @default.
• W3115202206 hasConcept C71924100 @default.
• W3115202206 hasConcept C75217442 @default.
• W3115202206 hasConcept C99454951 @default.
• W3115202206 hasConceptScore W3115202206C121608353 @default.
• W3115202206 hasConceptScore W3115202206C126322002 @default.

• next